Free Trial

Standard BioTools (LAB) Financials

Standard BioTools logo
$1.16 +0.03 (+2.65%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.14 -0.02 (-2.07%)
As of 04/17/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Standard BioTools

Annual Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-59 -190 -75 -185
Consolidated Net Income / (Loss)
-59 -190 -75 -139
Net Income / (Loss) Continuing Operations
-59 -190 -75 -139
Total Pre-Tax Income
-64 -193 -74 -138
Total Operating Income
-67 -116 -77 -175
Total Gross Profit
69 37 50 84
Total Revenue
131 98 106 174
Operating Revenue
131 98 106 174
Total Cost of Revenue
61 61 56 90
Operating Cost of Revenue
61 61 56 90
Total Operating Expenses
137 153 127 259
Selling, General & Admin Expense
99 102 88 157
Research & Development Expense
38 37 26 62
Restructuring Charge
- 14 14 40
Total Other Income / (Expense), net
3.80 -77 2.40 37
Interest Expense
3.82 4.33 4.57 3.32
Interest & Investment Income
0.00 2.23 5.57 20
Other Income / (Expense), net
7.62 -75 1.39 20
Income Tax Expense
-4.42 -2.83 0.45 0.57
Preferred Stock Dividends Declared
- 0.00 0.00 46
Basic Earnings per Share
($0.78) ($2.43) ($0.94) ($0.52)
Weighted Average Basic Shares Outstanding
75.79M 78.31M 79.16M 353.25M
Diluted Earnings per Share
($0.78) ($2.43) ($0.94) ($0.52)
Weighted Average Diluted Shares Outstanding
75.79M 78.31M 79.16M 353.25M
Weighted Average Basic & Diluted Shares Outstanding
77.20M 79.06M 290.12M 378.99M

Quarterly Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q2 2024 Q3 2024
Net Income / (Loss) Attributable to Common Shareholders
-29 -21 -17 -17 -21 -20 -46 -27
Consolidated Net Income / (Loss)
-29 -21 -17 -17 -21 -20 -46 -27
Net Income / (Loss) Continuing Operations
-29 -21 -17 -17 -21 -20 -46 -27
Total Pre-Tax Income
-30 -21 -17 -17 -21 -20 -46 -27
Total Operating Income
-29 -21 -17 -17 -21 -21 -51 -32
Total Gross Profit
9.22 11 12 14 11 13 15 23
Total Revenue
26 27 25 28 25 28 37 45
Operating Revenue
26 27 25 28 25 28 37 45
Total Cost of Revenue
16 16 13 14 14 15 22 22
Operating Cost of Revenue
16 16 13 14 14 15 22 22
Total Operating Expenses
38 32 29 31 32 35 65 55
Selling, General & Admin Expense
26 15 21 23 22 21 38 34
Research & Development Expense
8.49 7.43 6.43 6.18 6.37 6.97 19 13
Restructuring Charge
3.42 - 1.15 2.27 3.66 6.48 8.53 7.42
Total Other Income / (Expense), net
-1.11 0.34 0.01 0.71 0.23 1.45 4.86 4.90
Interest & Investment Income
0.00 62 0.07 0.24 0.34 4.92 4.44 3.94
Other Income / (Expense), net
-0.06 -61 -0.06 0.47 -0.12 1.10 0.41 0.96
Income Tax Expense
-0.71 0.07 0.26 0.30 0.05 -0.16 0.06 0.12
Preferred Stock Dividends Declared
- - 0.00 0.00 0.00 - 0.00 0.00
Basic Earnings per Share
($0.37) ($0.25) ($0.21) ($0.22) ($0.27) ($0.24) ($0.12) ($0.07)
Weighted Average Basic Shares Outstanding
78.90M 78.31M 79.08M 78.67M 79.15M 79.16M 372.33M 371.54M
Diluted Earnings per Share
($0.37) ($0.25) ($0.21) ($0.22) ($0.27) ($0.24) ($0.12) ($0.07)
Weighted Average Diluted Shares Outstanding
78.90M 78.31M 79.08M 78.67M 79.15M 79.16M 372.33M 371.54M
Weighted Average Basic & Diluted Shares Outstanding
79.30M 79.06M 78.38M 78.96M 79.40M 290.12M 371.15M 372.26M

Annual Cash Flow Statements for Standard BioTools

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Net Change in Cash & Equivalents
-40 53 -30 116
Net Cash From Operating Activities
-44 -89 -43 -143
Net Cash From Continuing Operating Activities
-44 -89 -43 -143
Net Income / (Loss) Continuing Operations
-59 -190 -75 -139
Consolidated Net Income / (Loss)
-59 -190 -75 -139
Depreciation Expense
3.65 3.50 3.98 13
Amortization Expense
13 11 9.94 -3.09
Non-Cash Adjustments To Reconcile Net Income
18 101 15 8.31
Changes in Operating Assets and Liabilities, net
-19 -14 2.73 -22
Net Cash From Investing Activities
-12 -88 20 363
Net Cash From Continuing Investing Activities
-12 -88 20 363
Purchase of Property, Plant & Equipment
-13 -3.83 -2.83 -8.36
Acquisitions
- 0.00 0.00 -1.39
Purchase of Investments
0.00 -137 -95 -256
Sale and/or Maturity of Investments
0.00 53 118 349
Other Investing Activities, net
1.32 0.00 0.00 280
Net Cash From Financing Activities
16 231 -6.81 -103
Net Cash From Continuing Financing Activities
16 231 -6.81 -103
Repayment of Debt
-0.50 -6.84 -2.08 -64
Repurchase of Common Equity
-0.08 -13 -5.41 -40
Issuance of Debt
17 25 0.00 0.00
Issuance of Preferred Equity
0.00 225 0.00 0.00
Issuance of Common Equity
1.49 0.82 0.72 0.92
Other Financing Activities, net
-1.79 -0.11 -0.04 0.69
Effect of Exchange Rate Changes
-0.02 -0.40 0.03 -0.79
Cash Interest Paid
3.15 3.49 3.82 3.09
Cash Income Taxes Paid
2.09 0.31 0.80 0.61

Quarterly Cash Flow Statements for Standard BioTools

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-14 21 32 29 -63 -28 -59 -43
Net Cash From Operating Activities
-25 -19 -8.49 -9.33 -11 -14 -28 -14
Net Cash From Continuing Operating Activities
-25 -19 -8.49 -9.33 -11 -14 -28 -14
Net Income / (Loss) Continuing Operations
-29 -21 -17 -17 -21 -20 -27 -34
Consolidated Net Income / (Loss)
-29 -21 -17 -17 -21 -20 -27 -34
Depreciation Expense
0.80 0.82 0.86 0.83 1.19 1.11 3.15 3.14
Amortization Expense
3.01 1.50 2.64 2.81 2.63 1.86 -1.05 -0.32
Non-Cash Adjustments To Reconcile Net Income
7.14 2.76 3.54 3.36 6.60 1.23 10 3.40
Changes in Operating Assets and Liabilities, net
-6.13 -3.42 1.32 0.71 -0.83 1.52 -13 14
Net Cash From Investing Activities
11 40 43 40 -50 -13 -31 26
Net Cash From Continuing Investing Activities
11 40 43 40 -50 -13 -31 26
Purchase of Property, Plant & Equipment
-1.26 -0.76 -1.01 -0.84 -0.91 -0.08 -2.26 -3.38
Purchase of Investments
- - -6.84 - -49 -39 -79 -30
Sale and/or Maturity of Investments
12 41 51 41 - 26 50 60
Net Cash From Financing Activities
-0.01 -0.27 -2.56 -2.08 -1.16 -1.00 -0.00 -55
Net Cash From Continuing Financing Activities
-0.01 -0.27 -2.56 -2.08 -1.16 -1.00 -0.00 -55
Repayment of Debt
- - 0.00 - -0.83 -1.25 - -55
Issuance of Common Equity
- 0.32 - - - 0.40 - 0.49
Other Financing Activities, net
-0.01 -0.03 -0.09 -0.04 0.07 0.02 -0.00 -0.01
Effect of Exchange Rate Changes
-0.28 0.32 0.02 -0.07 -0.15 0.23 -0.41 -0.27
Cash Interest Paid
0.17 1.65 0.23 1.69 0.25 1.65 0.00 1.44
Cash Income Taxes Paid
-0.39 0.06 0.31 0.21 0.12 0.17 0.06 0.20

Annual Balance Sheets for Standard BioTools

This table presents Standard BioTools' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Total Assets
275 390 323 612
Total Current Assets
72 209 158 376
Cash & Equivalents
28 81 52 167
Short-Term Investments
0.00 84 63 126
Accounts Receivable
18 17 20 34
Inventories, net
21 21 21 41
Prepaid Expenses
4.47 4.28 3.13 8.66
Plant, Property, & Equipment, net
28 26 24 43
Total Noncurrent Assets
175 156 141 194
Goodwill
106 106 106 111
Intangible Assets
28 13 1.40 29
Other Noncurrent Operating Assets
41 37 33 54
Total Liabilities & Shareholders' Equity
275 390 323 612
Total Liabilities
181 161 160 141
Total Current Liabilities
50 43 109 66
Short-Term Debt
6.84 2.08 60 0.00
Accounts Payable
11 7.91 9.24 12
Accrued Expenses
8.67 6.18 21 31
Current Deferred Revenue
15 14 15 17
Other Current Liabilities
3.05 3.68 4.32 6.23
Total Noncurrent Liabilities
131 117 51 75
Long-Term Debt
64 63 3.98 0.30
Noncurrent Deferred Revenue
5.97 3.82 3.52 33
Noncurrent Deferred & Payable Income Tax Liabilities
4.33 1.06 0.84 1.08
Other Noncurrent Operating Liabilities
57 49 42 41
Commitments & Contingencies
0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 311 311 0.00
Total Equity & Noncontrolling Interests
95 -81 -148 472
Total Preferred & Common Equity
95 -81 -148 472
Preferred Stock
0.00 0.00 0.00 0.00
Total Common Equity
95 -81 -148 472
Common Stock
832 847 861 1,703
Retained Earnings
-736 -926 -1,001 -1,186
Treasury Stock
0.00 -0.56 -5.98 -46
Accumulated Other Comprehensive Income / (Loss)
-0.91 -1.90 -2.22 1.23

Quarterly Balance Sheets for Standard BioTools

This table presents Standard BioTools' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q2 2024 Q3 2024
Total Assets
415 372 356 339 709 682
Total Current Assets
229 195 183 171 480 454
Cash & Equivalents
60 114 142 80 270 211
Short-Term Investments
125 41 0.00 49 125 156
Accounts Receivable
17 15 15 17 32 35
Inventories, net
22 23 22 22 43 43
Prepaid Expenses
4.61 3.37 3.57 3.40 10 9.32
Plant, Property, & Equipment, net
27 25 25 25 43 42
Total Noncurrent Assets
159 152 148 144 186 186
Goodwill
106 106 106 106 106 106
Intangible Assets
15 9.80 7.00 4.20 24 23
Other Noncurrent Operating Assets
38 36 35 34 56 56
Total Liabilities & Shareholders' Equity
415 372 356 339 709 682
Total Liabilities
166 158 158 160 198 192
Total Current Liabilities
46 44 47 52 124 121
Short-Term Debt
0.83 3.33 4.58 5.00 55 55
Accounts Payable
9.31 6.11 6.09 7.33 13 11
Accrued Expenses
6.91 6.88 7.18 10 32 32
Current Deferred Revenue
15 15 15 15 19 17
Other Current Liabilities
3.52 3.76 3.91 3.98 5.85 6.12
Total Noncurrent Liabilities
120 114 111 108 75 72
Long-Term Debt
64 62 61 60 0.30 0.30
Noncurrent Deferred Revenue
4.43 3.83 3.79 3.47 33 33
Noncurrent Deferred & Payable Income Tax Liabilities
0.62 1.05 1.05 1.02 0.84 0.84
Other Noncurrent Operating Liabilities
51 47 46 44 40 38
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
311 311 311 311 0.00 0.00
Total Equity & Noncontrolling Interests
-63 -97 -113 -132 510 489
Total Preferred & Common Equity
-63 -97 -113 -132 510 489
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-63 -97 -113 -132 510 489
Common Stock
845 850 854 857 1,683 1,689
Retained Earnings
-905 -943 -960 -981 -1,125 -1,152
Treasury Stock
- -3.03 -5.40 -5.80 -46 -46
Accumulated Other Comprehensive Income / (Loss)
-2.61 -1.33 -1.55 -1.95 -1.50 -1.41

Annual Metrics and Ratios for Standard BioTools

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric 2021 2022 2023 2024
Growth Metrics
- - - -
Revenue Growth
-5.47% -24.99% 8.57% 64.03%
EBITDA Growth
-36.20% -304.36% 65.27% -137.83%
EBIT Growth
-18.42% -218.90% 60.59% -106.35%
NOPAT Growth
-32.18% -72.26% 34.08% -128.77%
Net Income Growth
-11.73% -220.91% 60.73% -86.03%
EPS Growth
-5.41% -211.54% 61.32% 44.68%
Operating Cash Flow Growth
-185.79% -102.83% 51.56% -231.40%
Free Cash Flow Firm Growth
-410.55% -22.44% 49.97% -419.87%
Invested Capital Growth
9.97% -6.05% -13.25% 60.21%
Revenue Q/Q Growth
-4.63% -10.30% 1.11% 0.00%
EBITDA Q/Q Growth
13.42% -73.03% -2.61% 0.00%
EBIT Q/Q Growth
10.44% -61.57% -0.94% 0.00%
NOPAT Q/Q Growth
7.72% -9.26% -0.36% 0.00%
Net Income Q/Q Growth
12.67% -6.39% 1.41% 0.00%
EPS Q/Q Growth
14.29% -5.65% 1.05% 0.00%
Operating Cash Flow Q/Q Growth
-8.01% -15.78% 10.58% 0.00%
Free Cash Flow Firm Q/Q Growth
-15.85% -6.74% 10.09% 0.00%
Invested Capital Q/Q Growth
2.33% 0.65% -3.00% 0.00%
Profitability Metrics
- - - -
Gross Margin
53.13% 37.83% 47.44% 48.31%
EBITDA Margin
-33.42% -180.17% -57.64% -83.57%
Operating Margin
-51.66% -118.64% -72.03% -100.46%
EBIT Margin
-45.82% -194.82% -70.73% -88.97%
Profit (Net Income) Margin
-45.36% -194.08% -70.21% -79.62%
Tax Burden Percent
93.05% 98.53% 100.61% 100.41%
Interest Burden Percent
106.39% 101.10% 98.66% 89.12%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-36.05% -61.14% -44.55% -84.32%
ROIC Less NNEP Spread (ROIC-NNEP)
-120.97% 311.97% -16.92% -74.88%
Return on Net Nonoperating Assets (RNNOA)
-14.65% -56.07% 6.56% 40.57%
Return on Equity (ROE)
-50.71% -117.21% -37.99% -43.75%
Cash Return on Invested Capital (CROIC)
-45.55% -54.90% -30.36% -130.59%
Operating Return on Assets (OROA)
-19.95% -57.35% -21.09% -33.18%
Return on Assets (ROA)
-19.75% -57.13% -20.93% -29.70%
Return on Common Equity (ROCE)
-50.71% -4.74% 22.19% -22.30%
Return on Equity Simple (ROE_SIMPLE)
-62.62% 233.34% 50.43% -29.44%
Net Operating Profit after Tax (NOPAT)
-47 -81 -54 -123
NOPAT Margin
-36.16% -83.05% -50.42% -70.32%
Net Nonoperating Expense Percent (NNEP)
84.92% -373.11% -27.63% -9.43%
Return On Investment Capital (ROIC_SIMPLE)
- 490.76% 63.43% -25.99%
Cost of Revenue to Revenue
46.87% 62.17% 52.56% 51.69%
SG&A Expenses to Revenue
75.73% 104.43% 82.32% 89.78%
R&D to Revenue
29.06% 38.17% 24.40% 35.78%
Operating Expenses to Revenue
104.79% 156.47% 119.48% 148.77%
Earnings before Interest and Taxes (EBIT)
-60 -191 -75 -155
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-44 -176 -61 -146
Valuation Ratios
- - - -
Price to Book Value (P/BV)
3.17 0.00 0.00 1.38
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 1.97
Price to Revenue (P/Rev)
2.30 0.95 1.65 3.73
Price to Earnings (P/E)
0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.50 2.35 3.89 2.00
Enterprise Value to Revenue (EV/Rev)
2.62 3.09 4.09 2.06
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00
Leverage & Solvency
- - - -
Debt to Equity
0.75 0.28 0.39 0.00
Long-Term Debt to Equity
0.68 0.27 0.02 0.00
Financial Leverage
0.12 -0.18 -0.39 -0.54
Leverage Ratio
2.57 2.05 1.82 1.47
Compound Leverage Factor
2.73 2.07 1.79 1.31
Debt to Total Capital
42.89% 22.02% 28.01% 0.06%
Short-Term Debt to Total Capital
4.13% 0.71% 26.26% 0.00%
Long-Term Debt to Total Capital
38.76% 21.31% 1.76% 0.06%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 105.62% 137.29% 0.00%
Common Equity to Total Capital
57.11% -27.65% -65.30% 99.94%
Debt to EBITDA
-1.63 -0.37 -1.04 0.00
Net Debt to EBITDA
-0.98 0.57 0.84 2.01
Long-Term Debt to EBITDA
-1.47 -0.36 -0.07 0.00
Debt to NOPAT
-1.50 -0.80 -1.18 0.00
Net Debt to NOPAT
-0.90 1.24 0.96 2.39
Long-Term Debt to NOPAT
-1.36 -0.77 -0.07 0.00
Altman Z-Score
-2.89 -3.83 -3.94 0.12
Noncontrolling Interest Sharing Ratio
0.00% 95.95% 158.40% 49.02%
Liquidity Ratios
- - - -
Current Ratio
1.45 4.81 1.45 5.70
Quick Ratio
0.94 4.21 1.23 4.95
Cash Flow Metrics
- - - -
Free Cash Flow to Firm (FCFF)
-60 -73 -37 -190
Operating Cash Flow to CapEx
-332.18% -2,336.47% -1,529.04% -1,716.98%
Free Cash Flow to Firm to Interest Expense
-15.61 -16.87 -8.00 -57.30
Operating Cash Flow to Interest Expense
-11.53 -20.64 -9.48 -43.26
Operating Cash Flow Less CapEx to Interest Expense
-14.99 -21.52 -10.10 -45.78
Efficiency Ratios
- - - -
Asset Turnover
0.44 0.29 0.30 0.37
Accounts Receivable Turnover
5.97 5.50 5.76 6.55
Inventory Turnover
3.02 2.88 2.66 2.94
Fixed Asset Turnover
5.73 3.65 4.27 5.23
Accounts Payable Turnover
6.18 6.58 6.52 8.38
Days Sales Outstanding (DSO)
61.14 66.33 63.40 55.73
Days Inventory Outstanding (DIO)
120.80 126.76 137.16 124.01
Days Payable Outstanding (DPO)
59.10 55.49 56.00 43.55
Cash Conversion Cycle (CCC)
122.83 137.60 144.56 136.19
Capital & Investment Metrics
- - - -
Invested Capital
137 129 112 179
Invested Capital Turnover
1.00 0.74 0.88 1.20
Increase / (Decrease) in Invested Capital
12 -8.30 -17 67
Enterprise Value (EV)
342 303 435 359
Market Capitalization
300 93 175 651
Book Value per Share
$1.24 ($1.03) ($1.86) $1.27
Tangible Book Value per Share
($0.52) ($2.53) ($3.22) $0.89
Total Capital
166 295 227 472
Total Debt
71 65 64 0.30
Total Long-Term Debt
64 63 3.98 0.30
Net Debt
43 -101 -51 -293
Capital Expenditures (CapEx)
13 3.83 2.83 8.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.89 1.67 -6.48 17
Debt-free Net Working Capital (DFNWC)
29 167 108 310
Net Working Capital (NWC)
22 165 49 310
Net Nonoperating Expense (NNE)
12 109 21 16
Net Nonoperating Obligations (NNO)
43 -101 -51 -293
Total Depreciation and Amortization (D&A)
16 14 14 9.43
Debt-free, Cash-free Net Working Capital to Revenue
0.68% 1.71% -6.09% 9.81%
Debt-free Net Working Capital to Revenue
22.47% 170.96% 101.95% 177.71%
Net Working Capital to Revenue
17.23% 168.84% 45.97% 177.71%
Earnings Adjustments
- - - -
Adjusted Basic Earnings per Share
($0.78) ($2.43) ($0.94) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
75.79M 78.31M 79.16M 353.25M
Adjusted Diluted Earnings per Share
($0.78) ($2.43) ($0.94) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
75.79M 78.31M 79.16M 353.25M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
77.20M 79.06M 290.12M 378.99M
Normalized Net Operating Profit after Tax (NOPAT)
-47 -72 -44 -94
Normalized NOPAT Margin
-36.16% -73.34% -41.50% -54.08%
Pre Tax Income Margin
-48.75% -196.97% -69.78% -79.29%
Debt Service Ratios
- - - -
EBIT to Interest Expense
-15.65 -44.06 -16.47 -46.80
NOPAT to Interest Expense
-12.35 -18.78 -11.74 -36.99
EBIT Less CapEx to Interest Expense
-19.12 -44.94 -17.09 -49.32
NOPAT Less CapEx to Interest Expense
-15.82 -19.66 -12.36 -39.51
Payout Ratios
- - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.13% -6.90% -7.25% -29.15%

Quarterly Metrics and Ratios for Standard BioTools

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q2 2024 Q3 2024
Growth Metrics
- - - - - - - -
Revenue Growth
-10.03% -29.38% -5.23% 47.34% -1.09% 4.32% 34.48% 77.27%
EBITDA Growth
-147.65% -1,463.05% 61.15% 64.66% 30.90% 78.23% -275.53% -64.05%
EBIT Growth
-103.47% -792.95% 56.23% 59.37% 26.82% 75.23% -195.04% -44.51%
NOPAT Growth
-48.01% -87.51% 39.67% 54.75% 27.06% -1.30% -189.52% -49.81%
Net Income Growth
-112.57% -121.05% 77.92% 73.18% 28.64% 5.13% -168.30% -28.29%
EPS Growth
-105.56% -108.33% 78.79% 73.17% 27.03% 4.00% 45.45% 74.07%
Operating Cash Flow Growth
-159.23% -173.94% 45.57% 68.89% 53.63% 26.69% 0.00% -144.21%
Free Cash Flow Firm Growth
-1.79% 68.11% -382.28% 72.74% 85.76% 132.46% -1,346.95% -4,079.08%
Invested Capital Growth
-4.49% -6.05% 35.23% -4.98% -9.98% -13.25% 41.24% 54.60%
Revenue Q/Q Growth
36.58% 5.36% -7.04% 10.14% -8.31% 11.12% 0.00% 20.87%
EBITDA Q/Q Growth
33.03% -214.74% 16.55% -1.43% -30.94% 0.86% 0.00% 42.80%
EBIT Q/Q Growth
30.41% -181.51% 14.98% -1.99% -25.34% 4.70% 0.00% 38.61%
NOPAT Q/Q Growth
24.73% 27.27% 21.40% -5.16% -21.34% -1.01% 0.00% 37.22%
Net Income Q/Q Growth
53.69% 29.16% 19.20% -1.17% -23.22% 5.82% 0.00% 41.08%
EPS Q/Q Growth
54.88% 32.43% 16.00% -4.76% -22.73% 11.11% 0.00% 41.67%
Operating Cash Flow Q/Q Growth
17.93% 22.06% 55.76% -9.95% -22.33% -23.21% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
33.78% 54.69% -580.25% 86.65% 65.39% 203.26% 0.00% 0.05%
Invested Capital Q/Q Growth
0.73% 0.65% -3.31% -3.07% -4.58% -3.00% 0.00% 4.45%
Profitability Metrics
- - - - - - - -
Gross Margin
35.95% 41.33% 48.89% 49.17% 43.97% 47.58% 40.07% 51.73%
EBITDA Margin
-98.58% -294.49% -52.37% -48.23% -68.87% -61.45% -134.68% -63.74%
Operating Margin
-113.18% -78.13% -66.06% -63.07% -83.46% -75.87% -135.79% -70.53%
EBIT Margin
-113.43% -303.07% -66.29% -61.39% -83.92% -71.97% -134.68% -68.40%
Profit (Net Income) Margin
-114.74% -77.14% -67.05% -61.59% -82.77% -70.16% -122.88% -59.90%
Tax Burden Percent
97.63% 100.34% 101.59% 101.80% 100.24% 99.19% 100.12% 100.44%
Interest Burden Percent
103.61% 25.37% 99.57% 98.56% 98.40% 98.28% 91.13% 87.19%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-66.01% -40.27% -41.19% -37.55% -50.50% -46.92% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-44.76% -19.45% 12.65% -33.24% -43.82% -40.61% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
11.03% 3.50% -1.04% 15.77% 18.91% 15.74% 0.00% 0.00%
Return on Equity (ROE)
-54.98% -36.77% -42.23% -21.79% -31.60% -31.19% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)
-52.21% -54.90% -97.95% -42.43% -33.41% -30.36% 0.00% 0.00%
Operating Return on Assets (OROA)
-35.53% -89.21% -19.89% -16.25% -23.40% -21.46% 0.00% 0.00%
Return on Assets (ROA)
-35.94% -22.71% -20.12% -16.30% -23.09% -20.92% 0.00% 0.00%
Return on Common Equity (ROCE)
-5.78% -1.49% 13.42% 6.97% 14.36% 18.21% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)
284.77% 0.00% 134.48% 74.22% 57.49% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-20 -15 -12 -12 -15 -15 -35 -22
NOPAT Margin
-79.23% -54.69% -46.24% -44.15% -58.42% -53.11% -95.05% -49.37%
Net Nonoperating Expense Percent (NNEP)
-21.25% -20.81% -53.84% -4.31% -6.69% -6.31% -4.97% -2.52%
Cost of Revenue to Revenue
64.05% 58.67% 51.11% 50.84% 56.03% 52.42% 59.93% 48.27%
SG&A Expenses to Revenue
102.71% 55.46% 84.78% 81.69% 87.88% 75.76% 101.26% 76.50%
R&D to Revenue
33.09% 27.48% 25.59% 22.35% 25.11% 24.71% 51.67% 29.26%
Operating Expenses to Revenue
149.13% 119.46% 114.95% 112.24% 127.43% 123.45% 175.86% 122.26%
Earnings before Interest and Taxes (EBIT)
-29 -82 -17 -17 -21 -20 -50 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-25 -80 -13 -13 -17 -17 -50 -29
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 1.29 1.46
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 1.73 1.99
Price to Revenue (P/Rev)
0.79 0.95 1.60 1.43 2.18 1.65 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.17 2.35 3.02 3.19 4.13 3.89 1.87 2.27
Enterprise Value to Revenue (EV/Rev)
2.54 3.09 3.89 3.66 4.53 4.09 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.26 0.28 0.30 0.33 0.36 0.39 0.11 0.11
Long-Term Debt to Equity
0.26 0.27 0.29 0.31 0.33 0.02 0.00 0.00
Financial Leverage
-0.25 -0.18 -0.08 -0.47 -0.43 -0.39 -0.59 -0.56
Leverage Ratio
2.00 2.05 2.72 1.69 1.76 1.82 1.50 1.53
Compound Leverage Factor
2.08 0.52 2.71 1.67 1.73 1.78 1.37 1.33
Debt to Total Capital
20.66% 22.02% 23.31% 24.80% 26.46% 28.01% 9.74% 10.14%
Short-Term Debt to Total Capital
0.27% 0.71% 1.19% 1.74% 2.05% 26.26% 9.69% 10.08%
Long-Term Debt to Total Capital
20.40% 21.31% 22.11% 23.06% 24.41% 1.76% 0.05% 0.05%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
99.37% 105.62% 111.49% 118.30% 127.50% 137.29% 0.00% 0.00%
Common Equity to Total Capital
-20.03% -27.65% -34.80% -43.09% -53.96% -65.30% 90.26% 89.86%
Debt to EBITDA
-0.63 -0.37 -0.71 -0.97 -1.08 -1.04 0.00 0.00
Net Debt to EBITDA
1.18 0.57 0.97 1.14 1.08 0.84 0.00 0.00
Long-Term Debt to EBITDA
-0.63 -0.36 -0.67 -0.90 -1.00 -0.07 0.00 0.00
Debt to NOPAT
-0.87 -0.80 -0.88 -1.11 -1.21 -1.18 0.00 0.00
Net Debt to NOPAT
1.62 1.24 1.21 1.31 1.20 0.96 0.00 0.00
Long-Term Debt to NOPAT
-0.86 -0.77 -0.84 -1.03 -1.12 -0.07 0.00 0.00
Altman Z-Score
-2.18 -2.91 -2.36 -2.60 -2.66 -3.37 0.00 0.00
Noncontrolling Interest Sharing Ratio
89.48% 95.95% 131.77% 131.98% 145.43% 158.40% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
4.96 4.81 4.45 3.91 3.30 1.45 3.88 3.76
Quick Ratio
4.39 4.21 3.86 3.36 2.81 1.23 3.45 3.33
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
-14 -6.48 -44 -5.89 -2.04 2.10 -85 -85
Operating Cash Flow to CapEx
-1,947.07% -2,540.53% -840.10% -1,113.25% -1,260.99% -18,026.92% 0.00% -1,235.88%
Free Cash Flow to Firm to Interest Expense
-13.63 -5.45 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-23.46 -16.12 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-24.67 -16.75 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.31 0.29 0.30 0.26 0.28 0.30 0.00 0.00
Accounts Receivable Turnover
7.04 5.50 6.45 8.09 6.21 5.76 0.00 0.00
Inventory Turnover
2.72 2.88 2.60 2.64 2.60 2.66 0.00 0.00
Fixed Asset Turnover
3.94 3.65 3.66 4.07 4.11 4.27 0.00 0.00
Accounts Payable Turnover
6.28 6.58 6.39 7.84 6.85 6.52 0.00 0.00
Days Sales Outstanding (DSO)
51.86 66.33 56.56 45.09 58.74 63.40 0.00 0.00
Days Inventory Outstanding (DIO)
134.40 126.76 140.43 138.37 140.55 137.16 0.00 0.00
Days Payable Outstanding (DPO)
58.14 55.49 57.16 46.58 53.28 56.00 0.00 0.00
Cash Conversion Cycle (CCC)
128.12 137.60 139.82 136.88 146.01 144.56 0.00 0.00
Capital & Investment Metrics
- - - - - - - -
Invested Capital
128 129 125 121 115 112 171 178
Invested Capital Turnover
0.83 0.74 0.89 0.85 0.86 0.88 0.00 0.00
Increase / (Decrease) in Invested Capital
-6.02 -8.30 32 -6.33 -13 -17 50 63
Enterprise Value (EV)
277 303 376 385 476 435 319 405
Market Capitalization
87 93 154 151 229 175 659 716
Book Value per Share
($0.80) ($1.03) ($1.23) ($1.45) ($1.67) ($1.86) $1.37 $1.32
Tangible Book Value per Share
($2.34) ($2.53) ($2.70) ($2.89) ($3.07) ($3.22) $1.02 $0.97
Total Capital
313 295 279 263 244 227 565 545
Total Debt
65 65 65 65 65 64 55 55
Total Long-Term Debt
64 63 62 61 60 3.98 0.30 0.30
Net Debt
-120 -101 -89 -77 -64 -51 -340 -311
Capital Expenditures (CapEx)
1.26 0.76 1.01 0.84 0.91 0.08 0.00 2.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.49 1.67 -0.06 -1.49 -4.91 -6.48 16 22
Debt-free Net Working Capital (DFNWC)
184 167 154 141 124 108 411 388
Net Working Capital (NWC)
183 165 151 136 119 49 356 333
Net Nonoperating Expense (NNE)
9.11 6.07 5.23 4.83 6.18 4.81 10 4.74
Net Nonoperating Obligations (NNO)
-120 -101 -89 -77 -64 -51 -340 -311
Total Depreciation and Amortization (D&A)
3.81 2.32 3.50 3.64 3.82 2.97 0.00 2.10
Debt-free, Cash-free Net Working Capital to Revenue
-1.36% 1.71% -0.07% -1.41% -4.67% -6.09% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
168.22% 170.96% 159.97% 133.53% 117.84% 101.95% 0.00% 0.00%
Net Working Capital to Revenue
167.46% 168.84% 156.52% 129.19% 113.09% 45.97% 0.00% 0.00%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
($0.37) ($0.25) ($0.21) ($0.22) ($0.27) ($0.24) ($0.12) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding
78.90M 78.31M 79.08M 78.67M 79.15M 79.16M 372.33M 371.54M
Adjusted Diluted Earnings per Share
($0.37) ($0.25) ($0.21) ($0.22) ($0.27) ($0.24) ($0.12) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding
78.90M 78.31M 79.08M 78.67M 79.15M 79.16M 372.33M 371.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
79.30M 79.06M 78.38M 78.96M 79.40M 290.12M 371.15M 372.26M
Normalized Net Operating Profit after Tax (NOPAT)
-18 -15 -11 -11 -12 -10 -29 -17
Normalized NOPAT Margin
-69.89% -54.69% -43.04% -38.41% -48.31% -37.02% -79.00% -37.82%
Pre Tax Income Margin
-117.52% -76.88% -66.01% -60.50% -82.58% -70.73% -122.73% -59.64%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
-27.73 -68.82 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-19.37 -12.42 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-28.94 -69.45 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-20.57 -13.05 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-7.05% -6.90% -11.92% -6.42% -7.66% -7.25% 0.00% 0.00%

Frequently Asked Questions About Standard BioTools' Financials

When does Standard BioTools's fiscal year end?

According to the most recent income statement we have on file, Standard BioTools' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Standard BioTools' net income changed over the last 3 years?

Standard BioTools' net income appears to be on an upward trend, with a most recent value of -$138.89 million in 2024, rising from -$59.24 million in 2021. The previous period was -$74.66 million in 2023.

What is Standard BioTools's operating income?
Standard BioTools's total operating income in 2024 was -$175.24 million, based on the following breakdown:
  • Total Gross Profit: $84.26 million
  • Total Operating Expenses: $259.50 million
How has Standard BioTools revenue changed over the last 3 years?

Over the last 3 years, Standard BioTools' total revenue changed from $130.58 million in 2021 to $174.43 million in 2024, a change of 33.6%.

How much debt does Standard BioTools have?

Standard BioTools' total liabilities were at $140.62 million at the end of 2024, a 12.0% decrease from 2023, and a 22.1% decrease since 2021.

How much cash does Standard BioTools have?

In the past 3 years, Standard BioTools' cash and equivalents has ranged from $28.45 million in 2021 to $166.73 million in 2024, and is currently $166.73 million as of their latest financial filing in 2024.

How has Standard BioTools' book value per share changed over the last 3 years?

Over the last 3 years, Standard BioTools' book value per share changed from 1.24 in 2021 to 1.27 in 2024, a change of 2.5%.



This page (NASDAQ:LAB) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners